WalterPayton
Posted - 59 minutes from now
$BLUE
Ntlacrsp
Posted - 48 minutes from now
$BLUE Doesn’t look like Walled Street was impressed with Blues Earnings today… $10M in revenue, extreme short runway, no product demand ?? I don’t believe blue will get the votes for a reverse split ?? I am praying for a hostile takeover but I am not sure there are any takers at this point?? It will be awhile before there is demand for LYFGENIA and blue sure doesn’t have the runway for waiting. Looks like others don’t see any value in blue … based on little revenue and no offers to buy?? But the beat goes on??
Rosvit
Posted - 7 minutes from now
$BLUE Its horrible..Price 0'36 USD IS JOKE?? FUCK CEO
Gdoubleup
Posted - 1 minute from now
$BLUE
gargoyl
Posted - 1 hour ago
$BLRX $BLUE watching MM on LTSE exchange playing both sides book
Gdoubleup
Posted - 1 hour ago
$BLUE test support .3648 IMO
BioTechChap
Posted - 1 hour ago
$BLUE No presentation with today's ER call? Can't find on IR page.
Stockgang1
Posted - 1 hour ago
$BLUE let’s goo! Any time now
blueb22
Posted - 1 hour ago
$BLUE - listened to ER call recording. All good and reassuring to me. Retail Investors: please don't play into the hands of fear mongering happening here. Yes, there few real investors and since long time and suffering a lot (like me too) with high average and this price dropping regardless of any new (even some good news) and are frustrated (I too am frustrated) and RS usually results in bad outcome for investors, but I beleive it will not be the case here as there is huge tailwind coming here in next few weeks and months to propel price higher. But then there are many posters here who are not real investors and not even retail shorts, they are paid bashers working for 'someone' (or more than one) to suppress and manipulate price here. I still believe in BLUE and we are getting closer to better days ahead. (I will post many of my views over the weeknd) Good Luck real investors. Fingers crossed 🤞
Noahman
Posted - 1 hour ago
$BLUE, sure. I truly believe their message.
Gdoubleup
Posted - 2 hours ago
$BLUE
Dkll303
Posted - 2 hours ago
$ADAP Yes this has been a POS for over 2 years , just like $BLUE
Pianomemo
Posted - 2 hours ago
$BLUE so basically they secured the financing until Cashflow even in 2025 and expect a revenue surge in next year. 27% guess they gonna cover now same as $ASTS $EBS $MARA
Tommystar2121
Posted - 2 hours ago
$BLUE only a matter of time a big biotech will gobble this company. PT $8
Tommystar2121
Posted - 2 hours ago
$BLUE Top buy out target.. 🎯
Stockgang1
Posted - 2 hours ago
$BLUE get on it while you can
Espre
Posted - 2 hours ago
$BLUE From the Q3 call - Blue management. There's currently 35M shares available to be issued, this will be maintained/fixed in a potential R/S. With a R/S of 20 to 1 or 15 to 1, that's like giving 20 to 15x of the value of your shares away. Looking for an argument that could justify that strategy, I'm turning more skeptical with every quarterly meeting. I see how it's a great way to reaquire control/ownership from current investors. Any argument as a current investor why it would be good to hold through that process?
Bio2015
Posted - 3 hours ago
$BLUE Worse case scenario would be bankruptcy. If so, then asset sale would be a boost to $BLUE SP. $VRTX CEO stated Casgevy a ’multi-billion dollar opportunity’. If so, and Lyfgenia/Zynteglo sales exceeds Casgevy, then Lyf/Zyn asset sale should easily be worth $1B+ to $BLUE investors.
Stockgang1
Posted - 3 hours ago
$BLUE here you go: bluebird bio’s commercial progress, including the strong demand for its gene therapies and the company’s ongoing efforts to expand access through reimbursement strategies. The presentation of updated clinical trial data at ASH 2024 highlights the continued development of its therapies for sickle cell disease and beta-thalassemia, and the stocks to have positive sentiment and growth!
mikeg1999
Posted - 3 hours ago
@Bio2015 you have two quarters worth of data and are trying to extrapolate that long term. the difference is that Casgevy ATCs are still ramping up while $BLUE already has all of its established sites. you also forget that Lyfgenia is only approved in the US whereas Casgevy is internationally approved. these just can’t be compared right now.
Bio2015
Posted - 3 hours ago
Sub-$100M $BLUE is beating $125B Goliath $VRTX $CRSP in SCD/TDT by patient starts. Amazing given disparity in financial resources. Despite unwarranted black box warning (no cancer cases from Lyfgenia with updated vector), physicians are choosing Lyfgenia/Zynteglo over Casgevy. From latest ER’s: Lyfgenia/Zynteglo with 52 patient starts YTD (excluding Skysona); Casgevy with 40. Q/Q Lyf/Zyn increased from 23 patients in 2nd Q to 29 patients in 3rd Q. Lyf/Zyn starts are accelerating. Casgevy patient starts flat Q/Q with 20 in each Q. This is huge long-term with Lyf/Zyn sales accelerating while Cas sales remaining flat. Long-term, as long as $BLUE Lyf/Zyn sales accelerating, $BLUE will survive/eventually thrive. If Lyf/Zyn sales were lagging Casgevy, then $BLUE investors should worry a lot. $BLUE just needs to get over short-term financing hump. By end of 2025, $BLUE should be a multi-bagger. Takes guts to hang onto a stock that is tanking everyday.
Pianomemo
Posted - 3 hours ago
$BLUE Imagine being a short here to short this to Oblivion. What if it turns and the ramp up just started? Take your bag and move along
look2theblue
Posted - 3 hours ago
$BLUE My sense is that the individuals short 47 million shares are a disappointed with today's earnings call. They were counting on bad news, but instead they got continued growth and new patient starts. Not good for their fake doom and gloom narrative.
Humperdink
Posted - 3 hours ago
$BLUE Reverse split approval will see Mass covering of short shares. Once the reverse split is enacted, we will have something called a super low float around 9 or 10 million. Shorts know if they try to cover with a low float it will push the share price into the stratosphere. Now imagine, andrew obenshain enacts a reverse split, then announces a partnership or other good news. The share price can go from $5 area to $40.00 or $50 in a split second kind of like it did with DRUG. Now Andrew does a smallish offering around $50.00 for a few hundred million bucks without adding massive dilution. Andrew wants a reverse split to benefit us. VOTE YES TO REVERSE SPLIT
blueb22
Posted - 3 hours ago
$BLUE - I agree. I wish their is good buyer and management agree to come to negotiation table and sale for $4-5 range, but it is hard in current situation where due to SP and this cash raise/dilution fear etc, they are able press BLUE and corner them to sale for even $2 and that is what they are doing now and very desperately here as once CMS OBA signed at end of Nov (hopefully CMS is on target with that timeline) and now we are seeing rev realization of $25m in Q4, $45-48m in Q1, $70m in Q2, and possibly $90m in Q3 (assuming 40 starts in Q1) and so on, this SP will fly higher once funding issue is resolved. BLUE need RS and may be some dilutive cash and atleast that tool to survive and fight this constant attacks.
Humperdink
Posted - 3 hours ago
$BLUE pretty sure I heard 30 patients booked q1. That's 90 million revenue and we still have another half a quarter to book another 30 patients for q1. If we book 60 patients for q1 the share price here can head parabolic and easily gap fill that $2.40. That's nearly 200 million revs for q1
Coolrunnniz
Posted - 3 hours ago
$BLUE Not voting in favor a r/s regardless of what the mentally unstable guy below me says. if break even is that close renegotiate with hercules.
Humperdink
Posted - 3 hours ago
$BLUE double bounce off 52 week low means the likelihood of a significant recovery is just starting here. With near 50 million shares short and revenue headed parabolic, expect a steady rise in share price. Revenue ramp has begun and will not reverse. Share price should start to reflect in the coming weeks. If Andrew can use the reverse split to our advantage, he will save good news until after reverse split and a super low float of 10 million shares. Price with short covering can head parabolic. This is no time to sit and watch as we will be headed much higher sooner than later. Pay attention and VOTE YES TO REVERSE SPLIT!!!
stock_master84
Posted - 3 hours ago
$BLUE All - u guys have no idea. Blue is done, there is ntg left. RS vote will go through, I mean they will find a way. They will do 20:1, the stock price will settle around $6 after RS, and OS at 10M, then they will raise $100M at $4-$5, that will be dilution 2-3 times of OS, so it will be a massive dilution. Chances that the share price will get to $2 are high… After it settles in $2 range we are back where we were earlier this year.
So the real question is do you stick around knowing RS and dilution this year is inevitable and you will loose another 50% from current level. And do you trust this management team to deliver this time? If the answer is No to either one, you sell and move on, if Yes to both u invest and pray hard. FYI - there is less than 1% chance they will get partner or BO, so that is off the table.